Analysts Have Conflicting Sentiments on These Healthcare Companies: Deciphera Pharmaceuticals (DCPH), Atara Biotherapeutics (ATRA) and Nkarta (NKTX)

TipRanksMay 16 10:10

Deciphera Pharmaceuticals: Hold Rating Amid Acquisition and Concerns Over Qinlock Sales

TipRanksMay 14 16:37

Deciphera Pharmaceuticals: A Hold Rating Amidst Ono Pharmaceutical Acquisition Offer

TipRanksMay 13 22:06

Deciphera Pharmaceuticals (DCPH.US): The 2024 Q1 financial report achieved revenue of US$44.99 million, with a previous value of US$334.45 million and an expected value of US$46.28 million; earnings per share was -0.52 US dollars, the previous value was -

Deciphera Pharmaceuticals (DCPH.US): The 2024 Q1 financial report achieved revenue of US$44.99 million, with a previous value of US$334.45 million and an expected value of US$46.28 million; earnings per share was -0.52 US dollars, the previous value was -0.60 US dollars, and the expected value was -0.55 US dollars.

Zhitong FinanceMay 10 21:21

Deciphera Pharmaceuticals | 10-Q: Quarterly report

Futu NewsMay 10 19:28 · Announcements

Analysts Offer Insights on Healthcare Companies: Alignment Healthcare (ALHC), Butterfly Network (BFLY) and Deciphera Pharmaceuticals (DCPH)

TipRanksMay 6 16:42